![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Quinn David I.
Publisher: Adis International
ISSN: 0312-5963
Source: Clinical Pharmacokinetics, Vol.48, Iss.3, 2009-01, pp. : 199-209
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Clinical Pharmacokinetics, Vol. 50, Iss. 12, 2011-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Plerixafor: In Patients with Non-Hodgkin's Lymphoma or Multiple Myeloma
Drugs, Vol. 69, Iss. 3, 2009-02 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Cytochrome P450 2C19 (CYP2C19) genotype appears to affect the efficacy of omeprazole
Inpharma, Vol. 1, Iss. 1221, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. :